Royce & Associates LP Continues to Hold Stake in Flexion Therapeutics, Inc. (FLXN)
Royce & Associates LP continued to hold its stake in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,000 shares of the specialty pharmaceutical company’s stock at the close of the 2nd quarter. Royce & Associates LP owned 0.16% of Flexion Therapeutics worth $1,011,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of FLXN. IFP Advisors Inc increased its position in shares of Flexion Therapeutics by 24.5% during the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares in the last quarter. BB&T Securities LLC purchased a new stake in Flexion Therapeutics in the 2nd quarter valued at $289,000. Asset Management One Co. Ltd. purchased a new stake in Flexion Therapeutics in the 1st quarter valued at $319,000. Janney Montgomery Scott LLC grew its holdings in Flexion Therapeutics by 32.4% in the 2nd quarter. Janney Montgomery Scott LLC now owns 17,970 shares of the specialty pharmaceutical company’s stock valued at $363,000 after buying an additional 4,395 shares in the last quarter. Finally, Monarch Partners Asset Management LLC grew its holdings in Flexion Therapeutics by 86.0% in the 2nd quarter. Monarch Partners Asset Management LLC now owns 19,310 shares of the specialty pharmaceutical company’s stock valued at $390,000 after buying an additional 8,930 shares in the last quarter. Hedge funds and other institutional investors own 82.75% of the company’s stock.
FLXN has been the subject of several analyst reports. Cantor Fitzgerald set a $40.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, May 22nd. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank Of Canada set a $44.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, September 11th. Finally, BMO Capital Markets restated a “buy” rating on shares of Flexion Therapeutics in a report on Tuesday, June 27th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $31.50.
Flexion Therapeutics, Inc. (NASDAQ FLXN) opened at 24.12 on Friday. Flexion Therapeutics, Inc. has a 1-year low of $15.93 and a 1-year high of $29.41. The company’s 50-day moving average price is $23.25 and its 200 day moving average price is $22.01. The firm’s market cap is $769.55 million.
Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). On average, equities analysts expect that Flexion Therapeutics, Inc. will post ($3.70) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/09/17/royce-associates-lp-continues-to-hold-stake-in-flexion-therapeutics-inc-flxn.html.
In related news, insider Yamo Deniz bought 1,375 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was bought at an average cost of $25.40 per share, for a total transaction of $34,925.00. Following the acquisition, the insider now directly owns 5,000 shares in the company, valued at $127,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders acquired 5,375 shares of company stock valued at $131,575. 15.98% of the stock is owned by company insiders.
Flexion Therapeutics Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics, Inc. (NASDAQ:FLXN).
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.